The importance of the second messengers calcium (Ca 2+ ) and diacylglycerol (DAG) in platelet signal transduction was established more than 30 years ago. However, while protein kinase C (PKC) family members were discovered as the targets of DAG, little is known about the molecular identity of the main Ca 2+ sensor(s). Here, we identify CalDAG-GEFI as a critical molecule in 
Introduction
Platelet thrombus formation at sites of vascular injury is a complex and dynamic process that occurs in several phases 1, 2 . Platelet pre-activation and tethering (transient adhesion) is mediated by the interaction of GPIbα with matrixbound von Willebrand factor (VWF), particularly in conditions of high shear.
Platelet activation and firm adhesion is then triggered by collagen exposed in the vessel wall and/or locally generated thrombin. Sustained integrin activation and the formation of stable thrombi further depend on persistent co-stimulatory signaling provided by the second wave agonists, thromboxane A 2 (TxA 2 ) and ADP, which are released from activated platelets [3] [4] [5] .
The central biochemical event in platelet aggregation is the agonistinduced inside-out activation of αIIbβ3 integrin. Most platelet agonists initiate intracellular signaling through the activation of phospholipase C (PLC), followed by the generation of the second messengers calcium (Ca 2+ ) and diacylgycerol (DAG). DAG is critical for protein kinase C (PKC) activation, a key event in platelet granule release and integrin activation. Platelets express at least 6 PKC isoforms, which have activating as well as inhibitory roles in platelet activation [6] [7] [8] [9] [10] .
Early studies with calcium ionophores established a role of Ca 2+ in integrin activation, TxA 2 generation and granule release [11] [12] [13] . Initially, Ca 2+ -binding classical isoforms of protein kinase C (PKC) were suggested as the cell's main signal integrators for elevated intracellular-Ca However, more recent studies using calcium chelators in combination with broad
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From 4 range PKC inhibitors identified an independent Ca 2+ -sensitive signaling pathway that acts synergistically with PKC in the activation of integrin αIIbβ3 14, 15 . Whereas the role of Ca 2+ and DAG/PKC in various aspects of platelet activation has been well documented, the molecular nature of the Ca 2+ sensor(s) and the interplay between Ca 2+ -and DAG-driven signaling pathways have been less clearly defined.
In our recent work, we have identified Ca 2+ and DAG regulated guanine nucleotide exchange factor I (CalDAG-GEFI, RasGRP2) as a key molecule regulating Ca 2+ -dependent activation of integrins in platelets 16, 17 . CalDAG-GEFI contains binding sites for Ca 2+ and DAG and a guanine nucleotide exchange factor (GEF) domain catalyzing the activation of small GTPases of the Ras family, in particular Rap1 and Rap2
18
. In platelets, Rap1B accounts for 90% of the total Rap protein 19 and its importance in αIIbβ3 activation has recently been demonstrated in Rap1B-deficient mice 20 . Importantly, studies in cell types other than platelets demonstrated only very weak affinity of the C1 domain of CalDAG-GEFI for DAG in platelets 21, 22 , suggesting that it is predominantly regulated by binding of Ca 2+ to its EF hand domains. Several of our recent studies with platelets isolated from CalDAG-GEFI-deficient mice support this assumption.
First, platelet aggregation induced by Ca 2+ ionophores, but not by the phorbol ester PMA (DAG mimetic), was sensitive to CalDAG-GEFI expression 16 . Second, CalDAG-GEFI was critical for the rapid but reversible activation of Rap1 in thrombin-activated platelets, a process that depends on increased [Ca 2+ ]i 17 . And
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Rap1 has been extensively studied for its role in the regulation of cell 
Methods

Reagents and antibodies
Lovenox (enoxaparin sodium; Sanofi-Aventis, Bridgewater, NJ), heparin-coated capillaries (VWR, West Chester, PA), bovine serum albumin (BSA, fraction V), prostacyclin (PGI 2 ), human fibrinogen (type I) and U0126 (MEK inhibitor) (all from Sigma-Aldrich, St Louis, MO), 2-methylthio-AMP triethylammonium salt hydrate 
Aggregometry
Light transmission was measured in washed platelets activated in the presence of 50 μg/ml fibrinogen under stirring conditions at 37°C. Inhibitors and agonists were added at the indicated concentrations and light transmission was recorded over 10 minutes on a Chrono-log 4-channel optical aggregation system (Chronolog, Havertown, PA).
Thromboxane generation assay
Platelets were stimulated in standard aggregometry. At different time points, 50 μl of sample was withdrawn and 5mM EDTA/1mM aspirin was added. The cells were removed by centrifugation and TxB 2 levels were determined in the supernatant by enzyme immunoassay (Assay Designs, Ann Arbor, MI). TxB 2 is the stable product of the non-enzymatic hydration of TxA 2 , which itself has a halflife of only 37 seconds under physiological conditions.
Serotonin Release
Washed platelets were incubated for 30 minutes at 37°C with Rap1 according to the protocol previously described 16 . Briefly, Rap1-GTP was precipitated from lysates using RalGDS-RBD beads (Millipore, Billerica, MA).
Western Blotting
Total protein lysates and precipitated proteins were separated on 4-12% or 4-20% SDS-PAGE gradient gels and transferred to PVDF membranes.
Phosphorylated and non-phosphorylated ERK1/2 and Rap1 were detected with rabbit polyclonal antibodies. PKC-dependent protein phosphorylation was evaluated using a rabbit anti phospho-(Ser) PKC substrate antibody. After incubation with anti-rabbit antibodies, conjugated to horseradish peroxidase (Vector Laboratories, Burlingame, CA), immunoreactivity was detected by 1 1 Western Lightning enhanced chemiluminescence (G-Biosciences, Maryland
Heights, MO).
Flow chamber assay
Whole blood anticoagulated with heparin (30 U/ml low molecular weight heparin, Lovenox) was perfused at a shear rate of 400 sec -1 over bovine type I collagencoated glass slides (PureCol, 300 μg/ml Inamed Biomaterials, Fremont, CA) in a parallel-plate flow chamber. Platelet adhesion was visualized with a Nikon Ti-U inverted microscope (Nikon Instruments Inc., Melville, NY) equipped with a Retiga EXL monochrome camera (QImaging, Surrey, Canada). Images were analyzed using Nikon NIS Elements software. After 5 minutes of perfusion, the number of firmly adherent platelets was determined in three separate areas (0.02
). The experiment was repeated 3 times for each genotype.
Statistics
Results are reported as mean ± SEM. Statistical significance was assessed by unpaired 2-tailed Student t test. A P value less than 0.05 was considered significant.
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Results
The generation of TxA 2 and ADP is crucial for platelet aggregation in response to stimulation of the main collagen receptor, GPVI. To test whether CalDAG-GEFI is critical for GPVI-induced formation of second wave mediators, we first studied TxA 2 generation in CalDAG-GEFI-/-platelets activated with the non-physiological agonist convulxin (Cvx). As shown in Figure 1A , TxA 2 generation, as measured by the formation of its stable analog TxB 2 , was completely abolished in knockout platelets stimulated with low dose Cvx (100 ng/ml). In response to high dose (500 ng/ml) of the agonist, TxA 2 production was generation was secondary to the defect in integrin activation observed in knockout platelets, we determined TxA 2 release from platelets activated in the presence or absence of a blocking antibody to αIIbβ3. Integrin inhibition marginally reduced TxA 2 production in both WT and CalDAG-GEFI-/-platelets. However, there was a significant difference in TxA 2 release between CalDAG-GEFI-deficient and αIIbβ3-inhibited WT platelets (P < 0.05, Figure 1F ), demonstrating that CalDAG-GEFI contributes to TxA 2 generation independent of its role in integrin inside-out signaling.
To further characterize the signaling pathways that lead to CalDAG-GEFIdependent and -independent TxA 2 generation, we compared the kinetics of Rap1 activation to that of ERK-MAPK phosphorylation. Both ERK phosphorylation and Rap1 activation were completely abolished in CalDAG-GEFI-/-platelets activated with 100 ng/ml convulxin ( Figure 2A ). When activated with 500 ng/ml Cvx, activation of both Rap1 and ERK were delayed ( Figure 2B ), and the residual activation observed in knockout platelets was abolished upon pretreatment of the cells with 2-MesAMP ( Figure 2C ).
In addition to convulxin, we studied platelets stimulated with fibrillar type I collagen ( Figure 3 ). Collagen activation led to ~40% more TxA 2 generation in WT platelets when compared to convulxin. TxA 2 release in collagen-activated CalDAG-GEFI-deficient platelets was markedly impaired and delayed ( Figure 3A ). Figure 3E ). In collagen-activated platelets, U0126
abolished ERK phosphorylation (unpublished data) while it reduced TxA 2 release by ~60%. Thus, the GPVI/Rap1/ERK-dependent signaling pathway accounts for ∼60% of the TxA 2 production in collagen-activated platelets. Based on these results, we speculated that the defect in TxA 2 generation explains why CalDAG-GEFI-/-platelets fail to aggregate in response to low concentrations of Cvx, and that addition of exogenous TxA 2 could restore aggregation of Cvx-stimulated knockout platelets. As expected, aggregation was observed in CalDAG-GEFI-/-platelets stimulated with threshold concentrations of the thromboxane mimetic, U46619, and low dose Cvx, but not with either agonist alone ( Figure 4A ). Aggregation was reversed by pretreatment with a broad range PKC inhibitor, Ro31-8220, or the P2Y12 inhibitor 2-MesAMP. Consequently, binding of JON/A-PE to mutant platelets co-stimulated with Cvx and U46619 was significantly higher than in mutant platelets activated with either agonist alone, or platelets activated with Cvx and U46619 in the presence of 2-MesAMP ( Figure   4B ). Thus, in CalDAG-GEFI-/-platelets activated with a low dose of a GPVI agonist, TxA 2 is required to trigger integrin activation through the CalDAG-GEFIindependent but PKC/P2Y12-dependent pathway.
To confirm this hypothesis, we evaluated the phosphorylation state of downstream targets of PKC, such as pleckstrin-1 (PLEK) 35 , in stimulated platelets. In WT platelets, PLEK phosphorylation was observed in response to threshold doses of Cvx or U46619. In contrast, PLEK phosphorylation was markedly reduced in CalDAG-GEFI-deficient platelets activated with low dose convulxin or low dose U46619. However, PLEK phosphorylation was restored in
CalDAG-GEFI-/-platelets activated with both Cvx and U46619 ( Figure 4C ). To Figure   4D ). Low dose Cvx stimulation induced the rapid release of serotonin from WT, but not CalDAG-GEFI-/-, platelets. However, a threshold dose of U46619 could partially restore Cvx-induced secretion. Secretion under these conditions was dependent on PKC activation, as it was blocked by the broad-range PKC inhibitor, Ro31-8220.
Based on these findings, we speculated that TxA 2 released from WT platelets might be able to induce the aggregation of CalDAG-GEFI-/-platelets activated with low dose collagen. As shown in Figure 5A , addition of 10% WT platelets partially restored aggregation of CalDAG-GEFI-/-platelets (62±23% of WT). In contrast, WT platelets pretreated with aspirin were unable to restore aggregation of knockout platelets (0% of WT). Furthermore, 10% of wild type platelets failed to restore aggregation of CalDAG-GEFI-/-platelets pretreated with a αIIbβ3-blocking antibody (5±1% of WT). Thus, TxA 2 released from the WT platelets provided a stimulatory signal required for α IIbβ3 activation in CalDAG-GEFI-/-platelets activated with low dose collagen. To confirm the generation of aggregates consisting of both WT and CalDAG-GEFI-/-platelets, we repeated these studies with calcein green-labeled WT and calcein red-labeled CalDAG-GEFI-/-platelets ( Figure 5B ). Fixed aggregates were visualized by fluorescence microscopy. As expected, green-labeled WT platelets recruited a large number of
red-labeled CalDAG-GEFI-/-platelets into the aggregates. Pretreatment with an αIIbβ3 blocking antibody, however, almost completely blocked the incorporation of knockout platelets.
In order to validate our findings under conditions of physiological flow, we tested the effect of exogenous thromboxane on the adhesion of CalDAG-GEFI-/-platelets to collagen in flow chamber studies ( Figure 6A ). While WT platelets formed thrombi on the collagen surface, only few CalDAG-GEFI-/-platelets were able to firmly adhere to collagen under these conditions. Addition of U46619 led to significantly more firm adhesion of CalDAG-GEFI-/-platelets ( Figure 6B ). The effect of U46619 was reversed by pretreating CalDAG-GEFI-/-platelets with 2-MesAMP, suggesting that exogenous thromboxane promotes adhesion of knockout platelets via an ADP/P2Y12-dependent mechanism.
For In addition to the GPVI-specific agonist convulxin, we have also stimulated platelets with fibrillar type I collagen, a physiological agonist that binds to both GPVI and integrin α2β1. In contrast to Cvx-activated platelets, collagen- . In addition to ERK, the MAPK family members JNK1 and p38 are present in platelets [51] [52] [53] . While p38 signaling has been linked to cPLA 2 phosphorylation in platelets stimulated by various agonists 54, 55 , no such role has been described for JNK1. In addition to MAPK signaling, Shattil and colleagues recently demonstrated that integrin outside-in signaling could directly affect the enzymatic activitity of a pool of cPLA 2 α bound to the integrin 56 . Independent of the mechanisms regulating this second pathway for collagen-induced TxA 2 formation, our studies demonstrate that GPVIdependent TxA 2 release requires signaling by CalDAG-GEFI and P2Y12, which synergize at the level of Rap1 and ERK activation.
A key finding of this study is the critical role of CalDAG-GEFI signaling in GPVI-dependent TxA 2 release (Figure 1 , we speculated that the aggregation/adhesion defects of CalDAG-GEFI-/-platelets to collagen 16 could be overcome by adding exogenous TxA 2 . Indeed, we were able to restore GPVI-dependent aggregation of CalDAG-GEFI-/-platelets by adding U46619 ( Figure , prevent thrombosis. Platelets treated with P2Y12 inhibitors rely on signaling by CalDAG-GEFI for Rap1 activation. CalDAG-GEFI-mediated Rap1 activation occurs rapidly, but it is reversible. Consequently, P2Y12 inhibitors markedly reduce GPVI-induced TxA 2 release and integrin activation is transient.
For
Under flow conditions, transient Rap1 activation does not allow stable platelet aggregates to form.
Future studies should be directed towards a better understanding of how P2Y12 signaling leads to Rap1 activation. In addition to CalDAG-GEFI, the Rap1-GEFs CalDAG-GEFIII, 60 PDZ-GEF1, 60 and Epac1 (cAMP-GEFI) 61 have been identified in platelets and may thus be involved. Rap1 activation is also regulated by GTPase-activating proteins (GAPs). In platelets, Rap1GAP2 was recently identified. 60 In other cell types, Gαi/o signaling was shown to promote ubiquitination and proteosomal degradation of Rap1GAP2, leading to enhanced Rap1 activity. 62 However, the role of the above mentioned RapGEFs or Rap1GAP2 in P2Y12/Gαi-dependent Rap1 activation in platelets has not been addressed. Another area of interest will be studies aimed at a better understanding of how Rap1 activation can be sustained in the absence of P2Y12 signaling, or how to speed up Rap1 activation in the absence of CalDAG-GEFI signaling. Success in these studies could lead to a marked improvement of antiplatelet therapy, as it would provide strategies for the development of an antidote to P2Y12 or CalDAG-GEFI inhibitors.
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For Figure Legends Data are shown as mean±SEM. The amount of TxB 2 released from collagenactivated platelets was defined as 100%. n=3. *P < 0.05, **P < 0.01, ***P < 0.001. 
